Atazanavir/ritonavir

From WikiProjectMed
Jump to navigation Jump to search

Atazanavir/ritonavir
Combination of
AtazanavirProtease inhibitor
RitonavirProtease inhibitor (pharmacokinetic booster)
Names
Trade namesRitovaz
Other namesAnzavir-R, ritonavir/atazanavir[1]
Clinical data
Routes of
use
By mouth[1]
Defined daily dose0.3 gram[2]
Legal
Legal status
  • In general: ℞ (Prescription only)

Atazanavir/ritonavir (ATV/r) is a fixed-dose combination medication used in the treatment of HIV/AIDS.[1] It combines atazanavir and ritonavir.[1] It may be used instead of lopinavir/ritonavir.[3] It is taken by mouth.[1]

Side effects are generally minimal.[3] They may include abdominal pain, diarrhea, yellowish skin, muscle pains, and headache.[3] Greater care should be taken in people with underlying liver problems.[3] Use in pregnancy appears to be safe.[4] In the combination atazanavir functions as a protease inhibitor and ritonavir functions to increase levels of atazanavir.[3]

The combination was approved for use in India in 2012, and is pending approval in the United States As of 2017.[1] It is on the World Health Organization's List of Essential Medicines.[5] The average cost per year is 281 USD in the developing world as of 2012.[3]

Dosage

The defined daily dose is 0.3 gram (by mouth) refers to atazanavir[2]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 "Atazanavir/ritonavir - Mylan Laboratories - AdisInsight". adisinsight.springer.com. Retrieved 29 June 2017.
  2. 2.0 2.1 "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 12 September 2020.
  3. 3.0 3.1 3.2 3.3 3.4 3.5 "Atazanavir + ritonavir (Addition) -- Adults". World Health Organization (WHO). Retrieved 29 June 2017.
  4. "Atazanavir/Ritonavir in Pregnancy". hivinsite.ucsf.edu. Retrieved 10 December 2017.
  5. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

External links

Identifiers: